- Trial phase
- Phase 1
- Time to market
- If Phase 1 data are positive, SEP-479 would still need to complete Phase 2 and Phase 3 trials before any potential FDA submission, placing a potential approval several years away (likely 2029-2031 at the earliest).
- Why 6/10
- The next hard catalyst is the Phase 1 topline data readout for SEP-479, guided for late 2026 or early 2027 (within approximately 2-5 months). SEP-479 is Septerna's lead wholly-owned clinical program and a major value driver, but the company also has a significant Novo Nordisk partnership and other pipeline programs (SEP-204 for Graves' disease), so this is not a single-asset binary.
The next catalyst for SEP-479 is the Phase 1 topline safety, PK and PD data readout, guided for late 2026 or early 2027. Positive data would validate the oral small-molecule approach against an injectable standard of care (YORVIPATH) and could drive SEPN shares higher given the strong analyst consensus. Negative data (safety signals or poor PK/PD) would be a significant setback for Septerna's lead wholly-owned program.
Price Chart
Executive Summary
SEP-479 is Septerna's lead wholly-owned clinical program: an oral small-molecule PTH1 receptor agonist in Phase 1 development for hypoparathyroidism, a rare disorder where the body does not produce enough parathyroid hormone. The Phase 1 trial (up to 150 healthy volunteers) began dosing in April 2026, with topline safety, pharmacokinetic and pharmacodynamic data expected in late 2026 or early 2027. Preclinical data presented at ENDO 2026 were described as promising. SEP-479 competes against Ascendis Pharma's approved injectable YORVIPATH and Entera Bio's early-stage oral PTH peptide. Septerna (SEPN) trades at ~$50.74 with a Strong Buy analyst consensus (mean target $56.78) and has major institutional backing including RA Capital, Driehaus, and Goldman Sachs, plus a $195M upfront Novo Nordisk partnership that funds operations into mid-2029.
How It Works
SEP-479 is an oral small-molecule drug designed to activate the PTH1 receptor (PTH1R), mimicking the body's natural parathyroid hormone (PTH). In hypoparathyroidism, the parathyroid glands do not produce enough PTH, leading to dangerously low calcium levels and high phosphate levels. By activating the PTH1 receptor orally, SEP-479 aims to restore calcium and phosphate balance without requiring daily injections like the current standard of care.
Trial Status
Phase 1 clinical trial initiated in April 2026, first participants dosed. The randomized, placebo-controlled trial is enrolling up to 150 healthy adults to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics. Topline data are anticipated in late 2026 or early 2027. Preclinical characterization was presented at the ENDO 2026 annual meeting in June 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 topline data readout for SEP-479 (guided late 2026 or early 2027)
- Phase 1 trial initiation for SEP-204 (Graves' disease, planned Q1 2027)
- Potential analyst days or conference presentations on SEP-479 data
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Septerna, Inc. PRESS-RELEASE SEPN ·Originating report